U.S. Physical Therapy, Inc.
USPH · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.15 | -1.46 | -0.95 | 2.18 |
| FCF Yield | 4.92% | 5.50% | 4.78% | 5.53% |
| EV / EBITDA | 18.30 | 19.19 | 17.29 | 16.64 |
| Quality | ||||
| ROIC | 4.34% | 5.59% | 5.23% | 8.35% |
| Gross Margin | 18.46% | 18.52% | 20.25% | 23.67% |
| Cash Conversion Ratio | 1.64 | 2.20 | 1.35 | 1.32 |
| Growth | ||||
| Revenue 3-Year CAGR | 6.67% | 6.90% | 9.36% | 0.89% |
| Free Cash Flow Growth | -9.53% | 44.53% | -26.27% | -26.15% |
| Safety | ||||
| Net Debt / EBITDA | 2.92 | 1.42 | 3.47 | 2.27 |
| Interest Coverage | 7.89 | 7.48 | 9.83 | 81.50 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | -154.35 | 0.00 |
| Cash Conversion Cycle | 42.62 | 28.41 | 26.52 | 39.77 |